Amicus Therapeutics: Business Model, SWOT Analysis, and Competitors 2026

Amicus Therapeutics, Inc. stands as a leading company in Healthcare. Generating $634.21 million in annual revenue (growing 23.7% year-over-year) and carrying a market capitalization of $4.50 billion, the company has cemented its position as a foundational player in the global Biotechnology landscape. Under the leadership of its leadership team, Amicus Therapeutics, Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines Amicus Therapeutics, Inc.'s business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating Amicus Therapeutics, Inc. as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define Amicus Therapeutics, Inc.'s position in the Biotechnology market today.

What You Will Learn

1. How Amicus Therapeutics, Inc. generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering Amicus Therapeutics, Inc.'s competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who Amicus Therapeutics, Inc.'s main competitors are and how the company compares on key financial metrics
4. Amicus Therapeutics, Inc.'s key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. Amicus Therapeutics, Inc.'s strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $634.21 million annual revenue (TTM), +23.7% YoY
• Market Cap: $4.50 billion — one of the largest companies in the Healthcare sector
• Profitability: Gross margin 88.5%, operating margin 8.6%, net margin -4.3%
• Free Cash Flow: $47.84 million
• Return on Equity: -11.6% — reflects current investment phase
• Employees: 511 worldwide

Who Owns Amicus Therapeutics, Inc.?

Amicus Therapeutics, Inc. is publicly traded on the NGM under the ticker symbol FOLD. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of Amicus Therapeutics, Inc. are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

Amicus Therapeutics, Inc. has approximately 0.31 billion shares outstanding, with float shares of 0.00 billion — the freely tradeable portion. The stock trades at $14.33 per share as of early 2026.

Amicus Therapeutics, Inc.'s Mission Statement

Amicus Therapeutics, Inc.'s strategic mission is aligned with its core business activities in the Biotechnology sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — Amicus Therapeutics, Inc.'s most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For Amicus Therapeutics, Inc., the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, Amicus Therapeutics, Inc.'s strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does Amicus Therapeutics, Inc. Make Money?

As of 2026, Amicus Therapeutics, Inc. generates $634.21 million in annual revenue (growing 23.7% year-over-year), with a 88.5% gross margin and 8.6% operating margin. Market capitalization stands at $4.50 billion. Here is how the company generates its revenue:

Amicus is well-positioned for growth due to its innovative pipeline, strategic partnerships, and focus on rare diseases, aligning with industry trends favoring personalized medicine and targeted therapies.

In 2026, management's strategic priorities center on operational efficiency, market share expansion, and disciplined capital allocation. Investors should review Amicus Therapeutics, Inc.'s latest annual report and quarterly earnings releases for the most current financial disclosures and strategic updates.

Amicus Therapeutics, Inc. Business Model Canvas

The Business Model Canvas framework provides a structured view of how Amicus Therapeutics, Inc. creates, delivers, and captures value.

Key Partners: Amicus Therapeutics, Inc.'s key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Biotechnology sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: Amicus Therapeutics, Inc.'s most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: Amicus Therapeutics, Inc.'s critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (511 employees), proprietary technology, and financial resources ($293.54M in cash).

Value Propositions: Amicus Therapeutics, Inc. delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Biotechnology market.

Customer Relationships: Amicus Therapeutics, Inc. maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: Amicus Therapeutics, Inc. reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: Amicus Therapeutics, Inc. serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: Amicus Therapeutics, Inc.'s major costs include cost of goods sold (11.5% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 91.4% of revenue.

Revenue Streams: Amicus Therapeutics, Inc. generates revenue through its core product and service offerings.

Amicus Therapeutics, Inc. Competitors

Amicus Therapeutics, Inc.'s main competitors include Amicus Therapeutics positioned for growth. The company operates in the Biotechnology segment of the Healthcare sector where competitive positioning is shaped by product quality, distribution scale, and brand strength.

Competitive Analysis

Amicus Therapeutics, Inc.'s competitive position in Biotechnology is defined by its $4.50B market capitalization and 88.5% gross margins. Key competitive advantages include brand recognition and operational scale in the Biotechnology market.

Amicus Therapeutics, Inc. SWOT Analysis

A SWOT analysis examines Amicus Therapeutics, Inc.'s internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Strong Margins: Amicus Therapeutics, Inc.'s gross margin of 88.5% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 8.6% demonstrates disciplined cost management even at scale.
• Revenue Growth: Revenue grew 23.7% year-over-year to $634.21M, indicating strong demand for Amicus Therapeutics, Inc.'s products and services and outperformance relative to many industry peers.

Weaknesses

• High Financial Leverage: With a debt-to-equity ratio of 161.3, Amicus Therapeutics, Inc. carries significant debt relative to equity. While manageable given its cash flow, elevated leverage limits financial flexibility and increases vulnerability to rising interest rates.

Opportunities

• Total Addressable Market: Amicus Therapeutics, Inc. operates in the Biotechnology segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Amicus Therapeutics, Inc.'s products and services.
• Strategic Acquisitions: With $293.54M in cash and strong free cash flow generation, Amicus Therapeutics, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Amicus Therapeutics, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Amicus Therapeutics, Inc.'s business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

Amicus Therapeutics, Inc. enters 2026 as a leading company in Healthcare, backed by $634.21 million in annual revenue and a -4.3% net profit margin. The company's 88.5% gross margins and $47.84 million in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in Amicus Therapeutics, Inc.'s core markets.

For investors and analysts, Amicus Therapeutics, Inc. represents an important company to understand within the Healthcare sector. Key metrics to track include revenue growth, margin trends, and competitive positioning updates.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – Amicus Therapeutics, SEC EDGAR – Amicus Therapeutics Filings, and Amicus Therapeutics's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. What does Amicus Therapeutics focus on?

Amicus Therapeutics, Inc. generated $634.21 million in annual revenue with a -4.3% net profit margin as of the latest reporting period. The company operates in the Biotechnology sector. For the most current information, consult Amicus Therapeutics, Inc.'s investor relations page.

2. What is the business model of Amicus Therapeutics?

Amicus Therapeutics, Inc. generates $634.21 million in annual revenue (TTM) with a 88.5% gross margin, growing 23.7% year-over-year. The company's revenue model is described in detail in the business model section above.

3. What are the main products of Amicus Therapeutics?

Amicus Therapeutics, Inc. generated $634.21 million in annual revenue with a -4.3% net profit margin as of the latest reporting period. The company operates in the Biotechnology sector. For the most current information, consult Amicus Therapeutics, Inc.'s investor relations page.

4. Who are the main competitors of Amicus Therapeutics?

Amicus Therapeutics, Inc. competes in the Biotechnology segment of the Healthcare sector. The competitor comparison table in this article outlines key peers by market cap, revenue, and margins. Competitive dynamics in Biotechnology center on product differentiation, pricing strategy, and distribution scale.

5. What are the potential opportunities for Amicus Therapeutics?

Amicus Therapeutics, Inc.'s key growth opportunities include: Amicus Therapeutics, Inc. operates in the Biotechnology segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this envi Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Amicus With $293.54M in cash and strong free cash flow generation, Amicus Therapeutics, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic rea

6. What challenges does Amicus Therapeutics face?

Amicus Therapeutics, Inc. faces the following external threats: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Amicus Therapeutics, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Amicus Therapeutics Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri Monitoring these risks is essential for investors tracking the company's long-term trajectory.

7. How is Amicus Therapeutics positioned for growth in the future?

Amicus Therapeutics, Inc.'s key growth opportunities include: Amicus Therapeutics, Inc. operates in the Biotechnology segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this envi Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Amicus With $293.54M in cash and strong free cash flow generation, Amicus Therapeutics, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic rea